|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
inhibits cell division
|
|
gptkbp:appointed_by
|
gptkb:cisplatin
gptkb:carboplatin
gptkb:gemcitabine
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2005
gptkb:FDA
|
|
gptkbp:contains
|
gptkb:paclitaxel
|
|
gptkbp:contraindication
|
neutropenia
severe liver impairment
hypersensitivity to paclitaxel
|
|
gptkbp:developed_by
|
gptkb:Abraxane
gptkb:Pacific_yew_tree
|
|
gptkbp:financial_performance
|
albumin
|
|
gptkbp:formulation
|
nanoparticle albumin-bound
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nab-paclitaxel
|
|
gptkbp:ingredients
|
C47 H51 N O14 S
|
|
gptkbp:is_associated_with
|
quality of life improvements
improved survival rates
tumor shrinkage
|
|
gptkbp:is_available_in
|
lyophilized powder
vial form
|
|
gptkbp:is_compared_to
|
gptkb:docetaxel
gptkb:paclitaxel
gptkb:gemcitabine
|
|
gptkbp:is_considered
|
gptkb:municipality
|
|
gptkbp:is_evaluated_by
|
phase I trials
phase II trials
phase III trials
|
|
gptkbp:is_part_of
|
combination therapy
adjuvant therapy
neoadjuvant therapy
breast cancer regimen
lung cancer regimen
pancreatic cancer regimen
|
|
gptkbp:is_studied_in
|
other cancers
|
|
gptkbp:is_used_for
|
treatment of pancreatic cancer
treatment of breast cancer
treatment of non-small cell lung cancer
|
|
gptkbp:is_used_in
|
palliative care
clinical trials
off-label uses
|
|
gptkbp:manager
|
IV
|
|
gptkbp:marketed_as
|
gptkb:Celgene_Corporation
|
|
gptkbp:side_effect
|
fatigue
nausea
peripheral neuropathy
hair loss
low blood cell counts
|
|
gptkbp:traded_on
|
gptkb:Abraxane
|
|
gptkbp:weight
|
853.9 g/mol
|
|
gptkbp:bfsParent
|
gptkb:ductal_adenocarcinoma
|
|
gptkbp:bfsLayer
|
4
|